Genetic and non‐genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus‐1‐infected children in Ethiopia

Genetic and non‐genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus‐1‐infected children in Ethiopia

Abstract Despite the potential for efavirenz (EFV) to be an effective alternative antiretroviral agent, its sources of wide inter‐ and intra‐individual pharmacokinetic (PK) variability are not well‐characterized in children. We investigated the effects of genetic and non‐genetic factors, including d...

Full description

Bibliographic Details
Main Authors:	Adugna Chala, Eliford Ngaimisi Kitabi, Jemal Hussien Ahmed, Birkneh Tilahun Tadesse, Tolossa Eticha Chaka, Eyasu Makonnen, Eleni Aklillu
Format:	Article
Language:	English
Published:	Wiley 2023-06-01
Series:	CPT: Pharmacometrics & Systems Pharmacology
Online Access:	https://doi.org/10.1002/psp4.12951

Similar Items

Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study
by: Adugna Chala, et al.
Published: (2021-12-01)

Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations
by: Sabina Mugusi, et al.
Published: (2020-02-01)

Rates and Correlates of Short Term Virologic Response among Treatment-Naïve HIV-Infected Children Initiating Antiretroviral Therapy in Ethiopia: A Multi-Center Prospective Cohort Study
by: Birkneh Tilahun Tadesse, et al.
Published: (2019-09-01)

Prevalence and Correlates of Pre-Treatment HIV Drug Resistance among HIV-Infected Children in Ethiopia
by: Birkneh Tilahun Tadesse, et al.
Published: (2019-09-01)

Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.
by: Eliford Ngaimisi, et al.
Published: (2013-01-01)

Constitutive androstane receptor and pregnane X receptor genotype influence efavirenz plasma concentration and CYP2B6 enzyme activity
by: Zelalem Petros, et al.
Published: (2022-06-01)

Population Pharmacokinetic, Pharmacogenetic, and Pharmacodynamic Analysis of Cyclophosphamide in Ethiopian Breast Cancer Patients
by: Jemal Hussien Ahmed, et al.
Published: (2020-04-01)

Efficacy and safety of praziquantel treatment against Schistosoma mansoni infection among pre-school age children in southern Ethiopia
by: Tafese Tadele, et al.
Published: (2023-12-01)

Prevalence and Determinants of <i>Schistosoma mansoni</i> Infection among Pre-School Age Children in Southern Ethiopia
by: Tafese Tadele, et al.
Published: (2023-06-01)

Variability of efavirenz plasma concentrations among pediatric HIV patients treated with efavirenz based combination antiretroviral therapy in Dar es Salaam, Tanzania
by: Selemani Saidi Sungi, et al.
Published: (2018-10-01)

Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients.
by: Getnet Yimer, et al.
Published: (2011-01-01)

Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania.
by: Sabina Mugusi, et al.
Published: (2012-01-01)

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children
by: Bienczak, A, et al.
Published: (2016)

Optimal single sampling time-point for monitoring of praziquantel exposure in children
by: Rajabu Hussein Mnkugwe, et al.
Published: (2021-09-01)

<i>CYP2D6</i> Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients
by: Jemal Hussien Ahmed, et al.
Published: (2019-09-01)

Safety Surveillance of Mass Praziquantel and Albendazole Co-Administration in School Children from Southern Ethiopia: An Active Cohort Event Monitoring
by: Tigist Dires Gebreyesus, et al.
Published: (2022-10-01)

Effect of Genetic Variations in Drug-Metabolizing Enzymes and Drug Transporters on the Pharmacokinetics of Rifamycins: A Systematic Review
by: Sileshi T, et al.
Published: (2022-06-01)

Effect of Dihydroartemisinin-Piperaquine on the Pharmacokinetics of Praziquantel for Treatment of <i>Schistosoma mansoni</i> Infection
by: Omary Mashiku Minzi, et al.
Published: (2021-04-01)

Population pharmacokinetics of ivermectin after mass drug administration in lymphatic filariasis endemic communities of Tanzania
by: Adam M. Fimbo, et al.
Published: (2023-12-01)

The Impact of First-Line Anti-Tubercular Drugs’ Pharmacokinetics on Treatment Outcome: A Systematic Review
by: Sileshi T, et al.
Published: (2021-01-01)

Prevalence, Intensity, and Correlates of Schistosomiasis and Soil-Transmitted Helminth Infections after Five Rounds of Preventive Chemotherapy among School Children in Southern Ethiopia
by: Tigist Dires Gebreyesus, et al.
Published: (2020-11-01)

Correlation of N-acetyltransferase 2 genotype and acetylation status with plasma isoniazid concentration and its metabolic ratio in ethiopian tuberculosis patients
by: Tesemma Sileshi, et al.
Published: (2023-07-01)

Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda.
by: Fillekes, Q, et al.
Published: (2011)

Effects of Efavirenz for the Treatment of HIV on the Basis of Genetic Polymorphisms
by: Brighty Elizabeth Kurian, et al.
Published: (2022-04-01)

Pharmacokinetic interactions between rifampicin and efavirenz in HIV-TB coinfections
by: Yenny
Published: (2009-12-01)

Pharmacokinetic interactions between rifampicin and efavirenz in HIV-TB coinfections
by: Yenny Yenny
Published: (2016-02-01)

Efficacy and safety of praziquantel preventive chemotherapy in Schistosoma mansoni infected school children in Southern Ethiopia: A prospective cohort study
by: Tigist Dires Gebreyesus, et al.
Published: (2023-03-01)

<i>CYP3A</i> and <i>CYP2B6</i> Genotype Predicts Glucose Metabolism Disorder among HIV Patients on Long-Term Efavirenz-Based ART: A Case-Control Study
by: Wondmagegn Tamiru Tadesse, et al.
Published: (2022-06-01)

Reduced efficacy of single-dose albendazole against Ascaris lumbricoides, and Trichuris trichiura, and high reinfection rate after cure among school children in southern Ethiopia: a prospective cohort study
by: Tigist Dires Gebreyesus, et al.
Published: (2024-01-01)

Parasite clearance, cure rate, post-treatment prophylaxis and safety of standard 3-day versus an extended 6-day treatment of artemether–lumefantrine and a single low-dose primaquine for uncomplicated Plasmodium falciparum malaria in Bagamoyo district, Tanzania: a randomized controlled trial
by: Lwidiko E. Mhamilawa, et al.
Published: (2020-06-01)

Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir
by: Supphachoke Khemla, et al.
Published: (2023-04-01)

Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis
by: Nathan W. Cummins, et al.
Published: (2015-07-01)

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling Within a Bayesian Framework to Identify Poor Metabolizers of Efavirenz (PM), Using a Test Dose of Efavirenz
by: Manoranjenni Chetty, et al.
Published: (2018-03-01)

Efavirenz in pregnancy
by: Polly Clayden, et al.
Published: (2010-11-01)

Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.
by: Byakika-Kibwika, P, et al.
Published: (2012)

Pharmacokinetics of Efavirenz 600mg in Combination with Rifampicin in Chinese HIV/TB Co-Infection Patients
by: Wang T, et al.
Published: (2023-07-01)

Genetics of severe combined immunodeficiency
by: Rajni Kumrah, et al.
Published: (2020-03-01)

Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.
by: Jackson K Mukonzo, et al.
Published: (2014-01-01)

Efavirenz-induced urolithiasis.
by: Wirth, G, et al.
Published: (2006)

Efavirenz and neuropsychiatric effects
by: Mukesh Dheda
Published: (2017-04-01)